Importance of an Early HIV Antibody Differentiation Immunoassay for Detection of Dual Infection with HIV-1 and HIV-2.
BACKGROUND
HIV-2 is primarily endemic in West Africa and India, however, in time of global migration, a possible HIV-2 infection or co-infection with HIV-1 should be recognized right at the time of HIV diagnosis, in order to enable optimized antiretroviral treatment. Laboratory HIV testing consists of a combined HIV1/2/O antibody + antigen screening test and subsequent confirmation and type differentiation by a serological test formatted as a multi-line or multi-spot assay. CDC has proposed a revised alternative HIV diagnostic strategy which, in case of a reactive result in a combined HIV1/2/O antibody + antigen screening test, comprises an HIV-1 nucleic acid test (NAT) for HIV confirmation instead of an antibody differentiation immunoassay (ADI). Only a negative NAT must be further investigated by an ADI, thus saving expenses for ADI in most instances. We have investigated this alternative strategy with respect to its recognition of dual HIV-1 and HIV-2 infection.


RESULTS
Anonymized data of HIV notifications of patients newly diagnosed with HIV in Switzerland between 2007 and 2014 were analysed retrospectively. In a total of 4'679 notifications, we found 35 HIV-2 infections, 9 (25.7%) of which were dually infected with HIV-1. In 7 of the 9 dual HIV-1 and HIV-2 infections, HIV-1 RNA testing at the time of HIV diagnosis was positive with concentrations from 102 to 94'300 copies/mL plasma. HIV-1 RNA data were not available for the other two cases.


CONCLUSIONS
The alternative CDC strategy would have missed the concomitant HIV-2 infection in at least 7, but probably even more, of the 9 dually infected patients, as the detectable HIV-1 RNA would have precluded a supplemental ADI. Early ADI is mandatory for diagnosis of dual HIV-1/HIV-2 infection and guidance of appropriate therapy.
Institute of Medical Virology, University of Zurich, CH-8057, Zurich, Switzerland.
Andrea
A
Zbinden
Maihof Praxis, CH-6004, Lucerne, Switzerland.
Roland
R
Dürig
Institute of Medical Virology, University of Zurich, CH-8057, Zurich, Switzerland.|Swiss National Center for Retroviruses, University of Zurich, CH-8057, Zurich, Switzerland.
Cyril
C
Shah
Institute of Medical Virology, University of Zurich, CH-8057, Zurich, Switzerland.|Swiss National Center for Retroviruses, University of Zurich, CH-8057, Zurich, Switzerland.
Jürg
J
Böni
Institute of Medical Virology, University of Zurich, CH-8057, Zurich, Switzerland.|Swiss National Center for Retroviruses, University of Zurich, CH-8057, Zurich, Switzerland.
Jörg
J
Schüpbach
D000328:Adult; D000956:Antigens, Viral / Q000097:blood*; D060085:Coinfection; D003937:Diagnosis, Differential; D018563:Disease Notification; D005260:Female; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D015498:HIV-2 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008297:Male; D008403:Mass Screening / Q000379:methods*; D012367:RNA, Viral / Q000235:genetics / Q000276:immunology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D013557:Switzerland / Q000453:epidemiology
D000956:Antigens, Viral; D015483:HIV Antibodies; D012367:RNA, Viral